Human EDA2R/TNFRSF27/XEDAR Alexa Fluor™ Plus 594-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB1093AFP594
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Specificity
Clonality
Host
Isotype
Applications
Blockade of Receptor-ligand Interaction
Western Blot
Formulation, Preparation, and Storage
Formulation
Shipping
Stability & Storage
Background: EDA2R/TNFRSF27/XEDAR
X-linked Ectodysplasin Receptor (XEDAR), also known as EDA2R and TNFRSF27, is an approximately 45 kDa transmembrane protein in the TNF receptor superfamily (1). Mature human XEDAR consists of a 136 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 140 aa cytoplasmic domain (2). Within the ECD, human XEDAR shares 87% aa sequence identity with mouse and rat XEDAR. A 55 kDa long isoform of human XEDAR carries a 21 aa insertion in the juxtamembrane cytoplasmic domain (3). A 20 kDa fragment of the ECD can be shed by metalloprotease mediated cleavage (4). XEDAR binds selectively to the EDA-A2 variant of Ectodysplasin (EDA), while the closely related receptor EDAR binds selectively to the EDA-A1 variant (2). Other than a 2 aa deletion in its TNF-like domain, EDA-A2 is identical to EDA-A1 (2). Mutations in both EDAR and EDA are associated with hypohidrotic ectodermal dysplasia (HED), a disorder of hair, tooth, and eccrine sweat gland morphogenesis (5). XEDAR itself is strongly associated with androgenetic alopecia (male hair loss) (6). XEDAR is widely expressed, notably in embryonic basal epidermal cells and maturing hair follicles (2, 7, 8). Even though it does not contain a cytoplasmic death domain, XEDAR can associate with Fas and induce EDA-A2 dependent apoptosis (7, 9). Its transcription is directly induced by p53, and XEDAR mediated cell death is p53 dependent (7, 10). XEDAR is down‑regulated in breast, colon, and lung cancers, particularly in cases with p53 mutations (7, 11). XEDAR also plays a role in EDA‑A2 induced skeletal muscle degeneration and osteoblast differentiation (8, 12).
References
- Pfeffer, K. (2003) Cytokine Growth Factor Rev. 14:185.
- Yan, M. et al. (2000) Science 290:523.
- Sinha, S.K. et al. (2002) J. Biol. Chem. 277:44953.
- Tanikawa, C. et al. (2010) Mol. Cancer Res. 8:855.
- Mikkola, M.L. (2009) Am. J. Med. Genet. 149A:2031.
- Prodi, D.A. et al. (2008) J. Invest. Dermatol. 128:2268.
- Tanikawa, C. et al. (2009) Oncogene 28:3081.
- Newton, K. et al. (2004) Mol. Cell. Biol. 24:1608.
- Sinha, S.K. and P.M. Chaudhary (2004) J. Biol. Chem. 279:41873.
- Brosh, R. et al. (2010) FEBS Lett. 584:2473.
- Punj, V. et al. (2010) Clin. Cancer Res. 16:1140.
- Chang, B. et al. (2007) Cancer Gene Ther. 14:927.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional EDA2R/TNFRSF27/XEDAR Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only